Ticker: LUCD

Snapshot - Lucid Diagnostics Inc. (NASDAQ: LUCD) Short take: Lucid is a commercial-stage diagnostics company pushing EsoGuard/EsoCheck to market. The business is showing clinical traction and reimbursement momentum but remains cash‑burning, loss-making and dependent on additional financing and pa...

Lucid Diagnostics Inc. (NASDAQ: LUCD) has reported its quarterly results for the period ending March 31, 2025. The financial statements reveal both positives and negatives regarding its ongoing difficulties and future prospects. Positive Aspects: Revenue for the first quarter stood at $0.828 mil...